Thomas Lars Andresen
Founder at Nanovi Radiotherapy A/S
Profile
Thomas Lars Andresen is the founder of MonTa Biosciences ApS, founded in 2014, and Nanovi Radiotherapy A, founded in 2012.
At Nanovi Radiotherapy A, he also holds the title of Director from 2012 to present.
Dr. Andresen's current job is as the Chief Executive Officer & Director at T-Cypher Bio Ltd.
since 2021.
He previously worked as the Head-Research & Development at LiPlasome Pharma A.
Dr. Andresen received his graduate and doctorate degrees from the Technical University of Denmark.
Dr. Andresen is also the founder of Torque Therapeutics, Inc.
Thomas Lars Andresen active positions
Companies | Position | Start |
---|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Founder | 2011-12-31 |
T-Cypher Bio Ltd.
T-Cypher Bio Ltd. Miscellaneous Commercial ServicesCommercial Services T-Cypher Bio Ltd. is a British biotechnology company. The company was founded in 2015. Thomas Lars Andresen has been the CEO of the company since 2021. | Chief Executive Officer | 2021-07-31 |
Former positions of Thomas Lars Andresen
Companies | Position | End |
---|---|---|
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Founder | - |
MonTa Biosciences ApS
MonTa Biosciences ApS BiotechnologyHealth Technology MonTa Biosciences ApS engages in research and development in biotechnology for cancer immunotherapy. Its technology offers a solution to deliver immune stimulating compounds directly to immune cells in the blood. The company was founded by Thomas Lars Andresen, Jonas Henriksen, and Simon Skjøde Jensen in August 2014 and is headquartered in Brønshøj, Denmark. | Founder | - |
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Chief Tech/Sci/R&D Officer | - |
Training of Thomas Lars Andresen
Technical University of Denmark | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Health Technology |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
MonTa Biosciences ApS
MonTa Biosciences ApS BiotechnologyHealth Technology MonTa Biosciences ApS engages in research and development in biotechnology for cancer immunotherapy. Its technology offers a solution to deliver immune stimulating compounds directly to immune cells in the blood. The company was founded by Thomas Lars Andresen, Jonas Henriksen, and Simon Skjøde Jensen in August 2014 and is headquartered in Brønshøj, Denmark. | Health Technology |
T-Cypher Bio Ltd.
T-Cypher Bio Ltd. Miscellaneous Commercial ServicesCommercial Services T-Cypher Bio Ltd. is a British biotechnology company. The company was founded in 2015. Thomas Lars Andresen has been the CEO of the company since 2021. | Commercial Services |
- Stock Market
- Insiders
- Thomas Lars Andresen